The Synedica Retatrutide 40mg Pen — How to Use Reta 40mg pens

The Synedica Retatrutide 40mg pen is a prefilled, all-in-one injection system. Unlike vial-based formats, you do not need to reconstitute or measure — the pen delivers precise dose increments directly. Each pen kit arrives with 12 disposable 32g 4mm needles and a detailed instruction booklet covering dosage, injection technique, storage, and side effect guidance.

Why Slow Escalation Matters

The most important thing to understand about any retatrutide protocol — before you look at a single dose number — is that the escalation schedule is not a suggestion. It is the mechanism that makes the treatment tolerable.

Clinical trial data makes this clear. In the Phase 2 retatrutide study, participants in the 8mg group who skipped the 2mg starting step and went straight to 4mg experienced nausea rates of 60%, compared to just 17% in those who started at 2mg and escalated gradually. The final weight loss outcomes between both groups were identical — but the drop-out rate and side effect burden were dramatically different.

The practical lesson: rushing the protocol offers no weight loss advantage and significantly increases the chance of side effects severe enough to cause you to stop treatment entirely. Slow is fast. Every week you spend at a lower dose is building the tolerance that will allow you to reach and maintain higher, more effective doses comfortably.

Synedica Pen Dose Increments Explained

The Synedica Retatrutide 40mg pen is calibrated to deliver four adjustable dose settings. Understanding how many doses each setting gives you helps you plan your pen usage across your full protocol.

During the standard new-user protocol (2.5mg for 4 weeks, then 5mg for weeks 5–8), a single 40mg pen covers the full first 8 weeks and provides additional doses beyond that depending on your escalation path. The instruction booklet in your kit walks through how to set each dose on the pen dial.

The Standard Week-by-Week Protocol

The Synedica Retatrutide dosage protocol is built around the same principles used in Eli Lilly’s Phase 3 TRIUMPH clinical trials — a conservative starting dose with increases no sooner than every four weeks. Here is the full sequence:

What to Expect at Each Stage

Here is a practical summary of the typical experience at each dose level, drawn from Phase 2 and Phase 3 trial data and clinical reporting:

Phase 3 TRIUMPH-1 data (80 weeks at the highest dose group) showed average body weight reductions of 25–28.3%, with 45.3% of participants achieving ≥30% weight loss. These results reflect sustained use at maintenance doses with the full titration protocol followed. (Source: Lilly, May 2026)

Managing Side Effects During Escalation

The most common side effects — nausea, vomiting, diarrhea, and constipation — are predictable and manageable with the right approach. Here are the most effective practical strategies, aligned with clinical guidance:

The Dysesthesia Effect

Retatrutide has a unique side effect not seen with semaglutide or tirzepatide: dysesthesia — a tingling, numbness or skin sensitivity sensation. In Phase 3 TRIUMPH-4, this appeared in around 20.9% of participants at the highest dose. It is generally mild and rarely leads to discontinuation. It is believed to be linked to glucagon receptor activation. If you notice tingling or heightened skin sensitivity, document it and mention it at your next provider check-in. It is not an emergency, but it should be tracked.

How Far to Go: 7.5mg vs 10mg

Not every user needs to escalate to the maximum 10mg dose. The right ceiling for you depends on how your body responds, your tolerance for side effects, and the weight loss progress you are making at lower doses.

Here is the clinical data by dose group from Phase 3 TRIUMPH-1 at 80 weeks:

• 4mg: average 17.6% body weight reduction
• 9mg: average 23.7% body weight reduction
• 12mg: average 25.0% body weight reduction

The jump from the 9mg to the 12mg group added approximately 1.3 percentage points of additional weight loss on average, while carrying a meaningfully higher side effect burden. For many users, the 7.5mg dose on the Synedica pen represents an excellent balance of efficacy and tolerability — delivering excellent results without pushing to maximum receptor saturation.

Injection Tips for Best Results

Site selection

The Synedica 32g 4mm needle is designed for subcutaneous (under the skin) injection. The three approved sites are the abdomen (at least 2 inches from the navel), the outer thigh, or the upper arm. The abdomen tends to offer the most consistent absorption for most users.

Storage

Store the pen in the refrigerator (2–8°C) until ready to use. Before injection, allow the pen to sit at room temperature for 30 minutes — cold injections are more likely to cause local discomfort. Do not freeze. The pen should not be left at room temperature for extended periods.

After injection

Apply gentle pressure to the injection site for 10–15 seconds with a clean swab. Do not rub. Rubbing can cause local bruising. Dispose of used needles in a sharps container — do not recap and re-use.

Missed doses

If you miss a dose, inject as soon as you remember — provided your next scheduled dose is at least 72 hours away. If your next scheduled dose is within 72 hours, skip the missed dose and resume your normal schedule. Never double-dose to compensate for a missed injection.

Frequently Asked Questions